Related Experiment Video
Updated: Jun 19, 2026
08:32
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Nebivolol: the somewhat-different beta-adrenergic receptor blocker
1II Medizinische Klinik für Kardiologie/Angiologie, Langenbeckstrasse 1, Mainz, Germany. tmuenzel@uni-mainz.de
Journal of the American College of Cardiology
|October 10, 2009
Summary
Nebivolol, a third-generation beta-blocker, improves endothelial function and offers benefits beyond standard beta-blockade for cardiovascular conditions. Its unique properties suggest potential advantages in treating hypertension and heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Nebivolol is a third-generation beta-blocker recently approved in the U.S.
- It exhibits direct vasodilator properties and high beta(1)-receptor affinity.
- Endothelial dysfunction is implicated in hypertension, coronary artery disease, and heart failure.
Purpose of the Study:
- To review the clinical applications and benefits of nebivolol.
- To highlight nebivolol's unique endothelium-agonistic properties.
- To discuss its potential advantages over other beta-blockers.
Main Methods:
- Review of existing clinical data and pharmacological studies on nebivolol.
- Comparison of nebivolol's properties with other beta-blockers.
- Analysis of nebivolol's effects on endothelial function and cardiovascular outcomes.
Main Results:
- Nebivolol demonstrates significant improvement in endothelial dysfunction through nitric oxide synthase stimulation and antioxidant effects.
- It possesses antihypertensive and anti-ischemic effects.
- Nebivolol shows beneficial effects on hemodynamics and prognosis in heart failure patients.
Conclusions:
- Nebivolol's endothelium-enhancing properties may offer additional therapeutic benefits in cardiovascular diseases.
- It presents a favorable side effect profile in certain patient groups.
- Further research is needed to compare nebivolol with other beta-blockers and assess its prognostic impact in hypertension.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...